Log in

Foghorn Therapeutics Stock Forecast, Price & News

+0.38 (+1.92 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $20.20
50-Day Range N/A
52-Week Range
Now: $20.20
Volume99,605 shs
Average Volume178,390 shs
Market Capitalization$721.04 million
P/E RatioN/A
Dividend YieldN/A
Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.96 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FHTX



Sales & Book Value

Annual SalesN/A



Market Cap$721.04 million
Next Earnings DateN/A
OptionableNot Optionable
+0.38 (+1.92 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FHTX News and Ratings via Email

Sign-up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Foghorn Therapeutics (NASDAQ:FHTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Foghorn Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Foghorn Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Foghorn Therapeutics?

Wall Street analysts have given Foghorn Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Foghorn Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for FHTX?

4 Wall Street analysts have issued 1 year price objectives for Foghorn Therapeutics' shares. Their forecasts range from $24.00 to $27.00. On average, they anticipate Foghorn Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 23.8% from the stock's current price.
View analysts' price targets for Foghorn Therapeutics

Who are some of Foghorn Therapeutics' key competitors?

Who are Foghorn Therapeutics' key executives?

Foghorn Therapeutics' management team includes the following people:
  • Mr. Adrian Gottschalk, Pres, CEO & Director (Age 45, Pay $662.62k)
  • Dr. Douglas G. Cole M.D., Founder & Director (Age 60)
  • Dr. Cigall Kadoch Ph.D., Founder & Director (Age 35, Pay $225k)
  • Dr. Carl Peter Decicco Ph.D., Chief Scientific Officer (Age 60, Pay $596k)
  • Dr. Samuel Agresta M.D., M.P.H., Chief Medical Officer (Age 47, Pay $416.67k)
  • Dr. Gerald R. Crabtree, Founder & Member of Scientific Advisory Board
  • Dr. Allan Reine, Chief Financial Officer (Age 45)
  • Mr. Carlos Costa, Sr. VP, People & Organization
  • Dr. Steven F. Bellon Ph.D., Sr. VP of Drug Discovery (Age 55)
  • Ms. Fanny Cavalie, Sr. VP, Bus. & Operations

When did Foghorn Therapeutics IPO?

(FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Foghorn Therapeutics' stock symbol?

Foghorn Therapeutics trades on the NASDAQ under the ticker symbol "FHTX."

When did the company's quiet period expire?

Foghorn Therapeutics' quiet period expired on Wednesday, December 2nd. Foghorn Therapeutics had issued 7,500,000 shares in its initial public offering on October 23rd. The total size of the offering was $120,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Foghorn Therapeutics' stock price today?

One share of FHTX stock can currently be purchased for approximately $20.20.

How big of a company is Foghorn Therapeutics?

Foghorn Therapeutics has a market capitalization of $721.04 million. Foghorn Therapeutics employs 85 workers across the globe.

What is Foghorn Therapeutics' official website?

The official website for Foghorn Therapeutics is foghorntx.com.

How can I contact Foghorn Therapeutics?

The company can be reached via phone at 617-586-3100.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.